Context Therapeutics (CNTX)

• Market cap: $104M
• 1 day: -2.65%
• 5 days: 6.8%
• 1 month: -4.35%
• 3 months: 29.75%
• 6 months: 80.48%
• Year to date: -7.56%
• 1 year: -19.12%
• 5 years: -78.43%
• 10 years: -78.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Employees: 9